Highlights:
- Mylab Discovery Solutions launches machine to automate molecular diagnostic tests
- The machine will also run RT-PCR tests for the novel Coronavirus
- It will be able to run 32 samples simultaneously which could be further increased
On Tuesday, Pune-based Mylab Discovery Solutions Pvt Ltd launched a machine which will automate the manual process of molecular diagnostic tests which will also include the RT-PCR tests for the novel Coronavirus.
However, the cost of the machine has not been disclosed by the company yet.
In March, Mylab received a commercial approval from the CDSCO or Central Drugs Standard Control Organisation for its COVID-19 kit which the company said was the first “Made in India” test kit to receive such approval from the regulator.
The machine which will be able to automate the molecular diagnostic tests will come as a compact bench-top machine which will automate lab processes like sample handling as well as preparing RT-PCR (Reverse Transcription- Polymerase Chain Reaction) ready tubes.
It will be a cartridge-based machine and will be able to run multiple samples simultaneously the company claimed in a statement.
This machine could be used for a wide range of RNA (Ribonucleic Acid) and DNA-based (Deoxyribonucleic Acid) tests including COVID-19 RT-PCR tests. The machine will also be able to take input of various sample types such as plasma, tissue, sputum and swab, it added.
Also Read: Almost 900 Railway Employees, Ex-Employees And Their Kin Test Positive For the Novel Coronavirus
Hasmukh Rawal, Managing Director (MD) of Mylab Discovery Solutions said, “To make India self-reliant in advanced diagnostics, Compact XL is our most ambitious project to date. Compact XL will replace the need of 700 sq ft of clean room lab with a 4×3 benchtop machine and reduce the need of 3-4 expert technicians to just one, saving operational costs for labs,”.
This machine will make sure that the RNA/ DNA tests such as the COVID-19 testing could be conducted without manual error and under minimal supervision and help reduce human effort, Rawal added.
In April, the company said that it is partnering with Serum India Chief Executive Officer (CEO), Adar Poonawalla and Chairman of AP Globale Abhijit Pawar to make sure the scale up and quick delivery of this COVID-19 testing kits can happen.
According to Adar Poonawalla, CEO of Serum Institute India, “scientific and technological breakthroughs are driving our fight against COVID-19. This revolutionary product, with multiple patents already filed, will be a giant leap in making testing accessible”.
Poonawalla added that this will eliminate the barriers in adopting the molecular diagnostics at the laboratories and also address the potential gaps in the demand and supply of the highly skilled technicians for the testing.
This machine will be able to run 32 samples simultaneously which the company claims could be further increased when the machines will be connected in a network.
Abhijit Pawar, Chairman of AP Globale said, “The work at Mylab goes a long way in making diagnostics affordable and making India Atmanirbhar in testing. Compact XL is the next step in the same direction,”.
